NCT06363071

Brief Summary

Our research focused on understanding the interplay between brain excitability and balance function in patients with Parkinson's disease (PD), alongside evaluating effective physical therapy methods. It highlights the prevalence of non-motor disorders and cognitive impairments among PD patients, including balance and postural issues, cognitive function decline, and gait instability. Additionally, it notes that PD patients exhibit abnormal electrophysiological responses, indicating altered central excitability.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P75+ for not_applicable parkinson-disease

Timeline
Completed

Started Jun 2022

Typical duration for not_applicable parkinson-disease

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 13, 2022

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

March 28, 2024

Completed
15 days until next milestone

First Posted

Study publicly available on registry

April 12, 2024

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2025

Completed
Last Updated

April 12, 2024

Status Verified

April 1, 2024

Enrollment Period

2.8 years

First QC Date

March 28, 2024

Last Update Submit

April 9, 2024

Conditions

Keywords

Gait InitiationBalance trainingAnticipatory postural adjustmentsPaired associative stimulation (PAS)Transcranial magnetic stimulation (TMS)

Outcome Measures

Primary Outcomes (9)

  • Balance Performance

    Measured by the duration the stance can be maintained. Unit:seconds(s)

    Baseline, 4 weeks and 8 weeks.

  • COP Path Length in Balance Tasks

    The total distance traveled by the COP over a specified period. Longer path lengths can indicate increased effort to maintain balance or greater instability. Unit:millimeters(mm)

    Baseline, 4 weeks and 8 weeks.

  • COP Displacement in Balance Tasks

    Measures of COP movement in the anterior-posterior (AP) and medial-lateral (ML) directions, offering insights into the directional tendencies of balance control. Unit:millimeters(mm)

    Baseline, 4 weeks and 8 weeks.

  • Motor Evoked Potentials (MEPs)

    MEPs are the electrical responses recorded from muscles following stimulation of the motor cortex. They reflect the efficiency of neural transmission from the cortex to the muscle. Unit:millivolts (mV)

    Baseline, 4 weeks and 8 weeks.

  • Intracortical Facilitation (ICF)

    ICF is measured by applying a pair of TMS pulses with a short interval (e.g., 8-15 ms) where the first (subthreshold) pulse is followed by a second (suprathreshold) pulse, leading to an increased amplitude of the MEP.

    Baseline, 4 weeks and 8 weeks.

  • Intracortical Inhibition (ICI)

    ICI is measured similarly to ICF but with a shorter inter-stimulus interval (e.g., 1-5 ms), resulting in a suppressed MEP amplitude. This suppression reflects inhibitory processes within the cortex.

    Baseline, 4 weeks and 8 weeks.

  • Walking Speed

    The time taken by participants to walk a standardized distance, typically expressed in centimeters per second (cm/s).

    Baseline, 4 weeks and 8 weeks.

  • Step Length

    The linear distance between the two ankles, typically expressed in centimeter(cm).

    Baseline, 4 weeks and 8 weeks.

  • Step Time

    The duration taken for one complete step, measuring from foot-off of one foot to the next foot-off of the same foot, usually expressed in seconds.

    Baseline, 4 weeks and 8 weeks.

Secondary Outcomes (7)

  • COP Velocity in Balance Tasks

    Baseline, 4 weeks and 8 weeks.

  • COP Area in Balance Tasks

    Baseline, 4 weeks and 8 weeks.

  • Double Support Time

    Baseline, 4 weeks and 8 weeks.

  • Single Support Time

    Baseline, 4 weeks and 8 weeks.

  • Swing Time

    Baseline, 4 weeks and 8 weeks.

  • +2 more secondary outcomes

Study Arms (5)

Stage 1:Healthy people

EXPERIMENTAL

To establish PAS baseline and reliability.

Procedure: Paired associative stimulation

Stage 2:PD people

EXPERIMENTAL

To establish stage 3 training protocol.

Procedure: Paired associative stimulation

Stage 3:PD people

NO INTERVENTION

Control group.

Stage 3: PD APA training group

EXPERIMENTAL

Weight shift training and APA feedback.

Other: Weight shift training and APA feedback

Stage 3:PD PAS group

EXPERIMENTAL

Using PAS to regulate brain plasticity

Procedure: Paired associative stimulation

Interventions

Use TMS combine ES to stimulate TA nerve and M1 cortical

Also known as: PAS group
Stage 1:Healthy peopleStage 2:PD peopleStage 3:PD PAS group

Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.

Also known as: • APA training group
Stage 3: PD APA training group

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may not qualify if:

  • Musculoskeletal injuries on legs.
  • Osteoporosis.
  • PD subjects:
  • \- Clinical diagnosis of Parkinson disease.
  • Musculoskeletal injuries on legs
  • Osteoporosis.
  • Any peripheral or central nervous system injury or disease patients.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chang Gung University

Taoyuan District, 333, Taiwan

RECRUITING

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 28, 2024

First Posted

April 12, 2024

Study Start

June 13, 2022

Primary Completion

March 31, 2025

Study Completion

May 31, 2025

Last Updated

April 12, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share

Locations